RYBREVANT Janssen-Cilag Pty Ltd
Product name
RYBREVANT
Sponsor
Accepted date
Apr-2024
Active ingredients
amivantamab
Proposed indication
For the treatment of non-small cell lung cancer (NSCLC).
Application type
C (new indication)
Publication date
Apr-2024